Amanda T Harrington
Overview
Explore the profile of Amanda T Harrington including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baker K, Flentie K, Spears B, Mozharov S, Roberts K, El Ganbour A, et al.
J Clin Microbiol
. 2023 Dec;
62(1):e0054623.
PMID: 38051069
The Selux Next-Generation Phenotyping (NGP) system (Charlestown, MA) is a new antimicrobial susceptibility testing system that utilizes two sequential assays performed on all wells of doubling dilution series to determine...
2.
Humphries R, Abbott A, Alby K, Bard J, Harrington A, Mathers A, et al.
J Clin Microbiol
. 2023 Oct;
61(11):e0069123.
PMID: 37823650
No abstract available.
3.
Chen F, Saab-Chalhoub M, Tao J, Harrington A, Albarillo F, Crone A, et al.
Am J Dermatopathol
. 2023 Feb;
45(4):237-241.
PMID: 36805355
Prototheca species are achlorophyllic algae that are a rare cause of infection in humans. It most commonly causes localized cutaneous disease and rarely disseminated infection. Immunocompromised patients have the highest...
4.
Kralicek S, Sitaraman L, Kuprys P, Harrington A, Ramakrishna B, Osman M, et al.
Gastroenterology
. 2022 Aug;
163(5):1321-1333.
PMID: 35948108
Background & Aims: There is debate whether atypical enteropathogenic Escherichia coli (aEPEC) causes disease in adults. aEPEC is commonly detected in symptomatic and asymptomatic individuals. aEPEC, in contrast to typical...
5.
Zhang S, Babady N, Hanson K, Harrington A, Larkin P, Leal Jr S, et al.
J Clin Microbiol
. 2021 Jan;
59(7):e0178420.
PMID: 33504591
Fungal infections are a rising threat to our immunocompromised patient population, as well as other nonimmunocompromised patients with various medical conditions. However, little progress has been made in the past...
6.
Wenzler E, Santarossa M, Meyer K, Harrington A, Reid G, Clark N, et al.
Open Forum Infect Dis
. 2020 Jan;
7(1):ofz545.
PMID: 31993456
Background: Infections due to multidrug-resistant pathogens are particularly deadly and difficult to treat in immunocompromised patients, where few data exist to guide optimal antimicrobial therapy. In the absence of adequate...
7.
Meyer K, Deraedt M, Harrington A, Danziger L, Wenzler E
Int J Antimicrob Agents
. 2019 Apr;
54(2):197-201.
PMID: 31034937
Objective: The optimal therapy for serious enterococcal infections, especially vancomycin-resistant enterococci (VRE), remains unclear, although combination therapy is often recommended. Oritavancin has demonstrated in-vitro activity against VRE, but data evaluating...
8.
Moritz D, Mena Lora A, Blumer B, Harrington A
Emerg Infect Dis
. 2018 Jun;
24(7):1382-1383.
PMID: 29912690
Cryptococcus gattii is a fungal pathogen endemic in tropical and subtropical regions. Isolated cases and outbreaks have been reported in areas of North America and Europe, expanding the distribution pattern...
9.
Hildenbrand C, Wedekind L, Li G, vonRentzell J, Shah K, Rooney P, et al.
J Med Virol
. 2018 May;
90(10):1611-1619.
PMID: 29797374
Cytomegalovirus (CMV) infection is a leading cause of loss of hearing, vision, and mental retardation in congenitally infected children. It is also associated with complications of organ transplant and opportunistic...
10.
Bunnell K, Wenzler E, Harrington A, Danziger L
Diagn Microbiol Infect Dis
. 2018 Feb;
90(4):335-336.
PMID: 29395714
Breakpoint changes may impact cephalosporin susceptibility rates in uncomplicated urinary tract infections (uUTIs). Applying the ≤16-mg/L breakpoint to urine cultures from adult women in an academic health system resulted in...